Latest Breaking News On - வாடிம் அலெக்ஸாண்ட்ரே - Page 2 : comparemela.com
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES has been approved and issued by the United States Patent and Trademark Office. The patent was issued as Patent Number US 11,021,536 B2 (https://tinyurl.com/yspjv89w).
This patent covers a method of use of a bi-specific antibody ( CDX ), one of the Company s original and lead product candidates, for conditioning bone marrow/hematopoietic stem cell ( BM/HSC ) transplantation. It also covers a composition of matter (a subset of sequences) of monoclonal antibodies against target proteins existing on the surface of hematopoietic stem cells/hematopoietic progenitors ( HSC/HP ), and/or a number of leukemias such as acute myeloid leukemia ( AML ) as well as a protein
New-york
United-states
United-kingdom
London
City-of
Peter-redmond
Lucy-williams
Vladislav-sandler
Charles-goodfellow
Vadim-alexandre
Duncan-vasey
Matthew-johnson